-
JBCRG-06
Evaluation of the response rate, the pathological response and the safety of neoadjuvant Letrozole for postmenopausal women with hormone receptor positive, operable and primary breast which confirmed SD or PD in prior anthracycline-containing chemotherapy.
- Status
-
Study Closed
- Objectives
-
- Subjects
-
- Endpoints
-
Primary endpoint: Response rate, Secondary endpoints: Pathological CR rate, Breast Conserving Surgery rate, Safety, Disease-free survival and Overall survival
- Trial Period
-
September 2007 - September 2015 (Registration: 3 years, Follow-up study: 5 years)
- Lead Principal Investigator
-
Masahiro Kashiwaba (Department of Surgery, Iwate Medical University)
- Target Sample Size
-
45
- Regimen
-
Letrozole 12(-18)w
- Source of Funding
-
Japan Breast Cancer Research Group (JBCRG)
- Conference Presentation
-
- Articles and Publications
-
- UMIN-ID
-
UMIN000001325
- jRCT
-
- Memo
-
- COI Disclosure
-
